|
Aug 26
|
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
|
Aug 7
|
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
|
|
Aug 6
|
Cellectis Provides Financial Results for the Second Quarter 2024
|
|
Jul 25
|
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
|
|
Jun 12
|
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
|
|
May 7
|
AstraZeneca concludes equity investment in Cellectis
|
|
May 6
|
AstraZeneca ups stake in Cellectis in latest cell therapy bet
|
|
May 6
|
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
|
|
May 2
|
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
|
|
Apr 29
|
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
|
|
Apr 22
|
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
|
|
Apr 10
|
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
|
|
Apr 8
|
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
|
|
Jan 16
|
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
|
|
Dec 22
|
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
|
|
Nov 8
|
Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript
|
|
Nov 6
|
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
|
|
Nov 2
|
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
|
|
Oct 3
|
Monthly information on share capital and company voting rights
|
|
Oct 3
|
These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird
|